Cure My Disease

Don't miss your cure!

 Log in / Sign up

Immune cocktail takes on tough brain cancer in kids

NCT ID NCT06514898

Recruiting now Disease control Sponsor: University of Florida Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This early-phase trial is testing whether a combination of immune-based treatments is safe and feasible for children and young adults (ages 4–30) with a recurrent form of medulloblastoma, a type of brain cancer. The treatment includes personalized dendritic cell vaccines, immune cells grown in the lab, stem cells, and an immune checkpoint blocker. Only 12 participants will be enrolled, and the main goal is to see if the therapy can be given without causing severe side effects.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance

TTRNA-DC vaccines with GM-CSF, TTRNA-xALT (adoptive T cells), and PD-1 blockade (immune checkpoint inhibitor)

What this could lead to

If this approach proves safe and feasible, it could point toward a new treatment option for children and young adults with recurrent medulloblastoma that is hard to treat.

What could go wrong

This is a very early (Phase 1) pilot study with only 12 participants, so it is designed mainly to test safety and feasibility, not effectiveness. The combination therapy is complex and may cause serious side effects, and it is not yet known if it will help control the cancer.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for RECURRENT GROUP 3 MEDULLOBLASTOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

medulloblastoma medulloblastoma non-WNT/non-SHH group 3 medulloblastoma non-WNT/non-SHH group 4

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

RECURRENT GROUP 3 MEDULLOBLASTOMA RECURRENT GROUP 4 (NON-SHH/NON-WNT) MEDULLOBLASTOMA

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • University of Florida Health

    RECRUITING

    Gainesville, Florida, 32608, United States

    Contact

    Contact Phone: •••-•••-•••• Email: •••••@•••••